A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults - Adaptive COVID-19 Treatment Trial (ACTT)

Ohmagari Norio0 个研究点目标入组 1,114 人开始时间: 2020年3月24日最近更新: 2023年10月17日

适应症

试验速览

阶段: 3 期
状态: 已完成
发起方
入组人数: 1,114

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

The data show that remdesivir was superior to placebo in shortening the recovery time in adults hospitalized with Covid-19 and had evidence of lower respiratory tract infection. Although serious adverse events occurred in 131 of 532 patients (24.6%) in the remdesivir group and 163 of 516 patients (31.6%) in the placebo group, no deaths were considered by the investigators to be related to treatment assignment.

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 20age old 至 ot applicable（—）
性别: All

入选标准

•1.Admitted to a hospital with symptoms suggestive of COVID-19 infection.
•2.Subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures.
•3.Understands and agrees to comply with planned study procedures.
•4.Agrees to the collection of oropharyngeal (OP) swabs.
•5.Male or non-pregnant female adult =>18 years of age at time of enrollment.
•6.Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR or other commercial or public health assay in any specimen collected < 72 hours prior to randomization.
•Note - 72 hours is not necessarily time from initial diagnosis. If => 72 hours since positive PCR, the PCR may be repeated to assess eligibility.
•7.Illness of any duration, and at least one of the following:
•-Radiographic infiltrates by imaging (chest x-ray, CT scan, etc.), OR
•-Clinical assessment (evidence of rales/crackles on exam) AND SpO2 <= 94% on room air, OR
•-Requiring supplemental oxygen, OR
•-Requiring mechanical ventilation.
•8.Women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through Day 29.
•9.Agrees to not participate in another clinical trial for the treatment of COVID-19 or SARS-CoV-2.

排除标准

•1.ALT/AST > 5 times the upper limit of normal.
•2.Estimated glomerular filtration rate (eGFR) < 50 or requiring dialysis.
•3.Pregnancy or breast feeding.
•4.Anticipated transfer to another hospital which is not a study site within 72 hours.
•5.Allergy to any study medication.

研究者

发起方

Ohmagari Norio

相似试验

终止

3 期

Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient SettingCOVID-19

NCT04501952Gilead Sciences584

已完成

不适用

Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 InfectionsCOVID-19

NCT04365725Assistance Publique - Hôpitaux de Paris84

终止

3 期

Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)COVID-19

NCT04745351Gilead Sciences249

已完成

3 期

Major Depressive Disorder In The ElderlyDepressive Disorder, Major

NCT00093288GlaxoSmithKline364

已完成

3 期

Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)Covid19

NCT06729593National Institute of Allergy and Infectious Diseases (NIAID)87